In this study, we demonstrated the antitumor efficacy of ALRN-6924, a dual inhibitor of Mdm4 and Mdm2, in ER+ breast cancer cell line models and identified significant synergy with combination of ALRN-6924 with chemotherapeutic agents. This evidence concerns the gene MDM2 and breast cancer.